<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Geriatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Geriatr</journal-id><journal-title-group><journal-title>BMC Geriatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2318</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28659161</article-id><article-id pub-id-type="pmc">5490153</article-id><article-id pub-id-type="publisher-id">522</article-id><article-id pub-id-type="doi">10.1186/s12877-017-0522-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dao</surname><given-names>Elizabeth</given-names></name><address><email>lizdao@mail.ubc.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Best</surname><given-names>John R.</given-names></name><address><email>john.best@ubc.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hsiung</surname><given-names>Ging-Yuek Robin</given-names></name><address><email>hsiung@mail.ubc.ca</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sossi</surname><given-names>Vesna</given-names></name><address><email>vesna@physics.ubc.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Jacova</surname><given-names>Claudia</given-names></name><address><email>cjacova@pacificu.edu</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tam</surname><given-names>Roger</given-names></name><address><email>roger.tam@ubc.ca</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu-Ambrose</surname><given-names>Teresa</given-names></name><address><phone>1-604-875-4111</phone><email>teresa.ambrose@ubc.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>Department of Physical Therapy, </institution><institution>University of British Columbia, </institution></institution-wrap>212 &#x02013; 2177 Wesbrook Mall, Vancouver, BC V6T 1Z3 Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>Djavad Mowafaghian Centre for Brain Health, </institution><institution>University of British Columbia, </institution></institution-wrap>2215 Wesbrook Mall, Vancouver, BC V6S 0A9 Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>Department of Medicine, </institution><institution>University of British Columbia, UBC Hospital S152, </institution></institution-wrap>2211 Wesbrook Mall, Vancouver, BC V6T 2B5 Canada </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>Department of Physics and Astronomy, </institution><institution>University of British Columbia, </institution></institution-wrap>6224 Agricultural Road, Vancouver, BC V6T 1Z1 Canada </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9069 6400</institution-id><institution-id institution-id-type="GRID">grid.261593.a</institution-id><institution/><institution>School of Graduate Psychology, Pacific University, </institution></institution-wrap>190 SE 8th Avenue, Hillsboro, OR 97123 USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>MS/MRI Research Group, </institution><institution>University of British Columbia, </institution></institution-wrap>2215 Wesbrook Mall, Vancouver, BC V6S 0A9 Canada </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1302 4958</institution-id><institution-id institution-id-type="GRID">grid.55614.33</institution-id><institution/><institution>Centre for Hip Health and Mobility, Robert H.N. Ho Research Centre, </institution></institution-wrap>2635 Laurel Street, Vancouver, BC V5Z 1M9 Canada </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>133</elocation-id><history><date date-type="received"><day>4</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">To determine the association between amyloid-beta (A&#x003b2;) plaque deposition and changes in global cognition, executive functions, information processing speed, and falls risk over a 12-month period in older adults with a primary clinical diagnosis of subcortical ischemic vascular cognitive impairment (SIVCI).</p></sec><sec><title>Methods</title><p id="Par2">This is a secondary analysis of data acquired from a subset of participants (<italic>N</italic>&#x000a0;=&#x000a0;22) who were enrolled in a randomized controlled trial of aerobic exercise (NCT01027858). The subset of individuals completed an <sup>11</sup>C Pittsburgh compound B (PIB) scan. Cognitive function and falls risk were assessed at baseline, 6-months, and 12-months. Global cognition, executive functions, and information processing speed were measured using: 1) ADAS-Cog; 2) Trail Making Test; 3) Digit Span Test; 4) Stroop Test, and 5) Digit Symbol Substitution Test. Falls risk was measured using the Physiological Profile Assessment. Hierarchical multiple linear regression analyses determined the unique contribution of A&#x003b2; on changes in cognitive function and falls risk at 12-months after controlling for experimental group (i.e. aerobic exercise training or usual care control) and baseline performance. To correct for multiple comparisons, we applied the Benjamini-Hochberg procedure to obtain a false discovery rate corrected threshold using alpha&#x000a0;=&#x000a0;0.05.</p></sec><sec><title>Results</title><p id="Par3">Higher PIB retention was significantly associated with greater decrements in set shifting (Trail Making Test, adjusted R<sup>2</sup>&#x000a0;=&#x000a0;35.3%, <italic>p</italic>&#x000a0;=&#x000a0;0.002), attention and conflict resolution (Stroop Test, adjusted R<sup>2</sup>&#x000a0;=&#x000a0;33.4%, <italic>p</italic>&#x000a0;=&#x000a0;0.01), and information processing speed (Digit Symbol Substitution Test, adjusted R<sup>2</sup>&#x000a0;=&#x000a0;24.4%, <italic>p</italic>&#x000a0;=&#x000a0;0.001) over a 12-month period. Additionally, higher PIB retention was significantly associated with increased falls risk (Physiological Profile Assessment, adjusted R<sup>2</sup>&#x000a0;=&#x000a0;49.1%, <italic>p</italic>&#x000a0;=&#x000a0;0.04). PIB retention was not significantly associated with change in ADAS-Cog and Verbal Digit Span Test (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05).</p></sec><sec><title>Conclusions</title><p id="Par4">Symptoms associated with SIVCI may be amplified by secondary A&#x003b2; pathology.</p></sec><sec><title>Trial registration</title><p id="Par5">ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01027858">NCT01027858</ext-link>, December 7, 2009.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Vascular cognitive impairment</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Amyloid</kwd><kwd>Cognitive impairment</kwd><kwd>Executive functions</kwd><kwd>Falls risk</kwd></kwd-group><funding-group><award-group><funding-source><institution>Canadian Stroke Network</institution></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004411</institution-id><institution>Heart and Stroke Foundation of Canada</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>Jack Brown &#x00026; Family Alzheimer&#x02019;s Research Foundation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par21">Alzheimer&#x02019;s disease (AD) and subcortical ischemic vascular cognitive impairment (SIVCI) are the two most common causes of cognitive dysfunction [<xref ref-type="bibr" rid="CR1">1</xref>], but people often present with mixed pathology [<xref ref-type="bibr" rid="CR2">2</xref>]. Pathological hallmarks of AD include the presence of amyloid-beta (A&#x003b2;) plaques and neurofibrillary tangles (NFT) [<xref ref-type="bibr" rid="CR3">3</xref>]. On the other hand, SIVCI is characterized by the presence of white matter hyperintensities (WMH) and lacunes. In the last decade, there is growing recognition of the high prevalence of mixed presentations [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] and many studies have begun to investigate the impact of cerebrovascular pathology in AD [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. However, few studies have considered mixed pathology from a primary SIVCI diagnosis perspective.</p><p id="Par22">It is important to consider AD pathology within an SIVCI diagnosis as both share common pathogenic mechanisms &#x02013; studies indicate a positive feedback loop effect between A&#x003b2; and cerebrovascular dysfunction. For example, A&#x003b2; may cause vascular dysregulation by compromising cerebral perfusion, reducing vascular reserves, and increasing the propensity for ischemic damage. In return, hypoxia and/or ischemia may promote the production of the A&#x003b2; peptide resulting in greater A&#x003b2; plaque accumulation [<xref ref-type="bibr" rid="CR8">8</xref>]. Molecular studies indicate a close interaction between AD and SIVCI pathology [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]; yet, few studies have been conducted to investigate the association between A&#x003b2; and cognitive function in SIVCI [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par23">Furthermore, elevated levels of A&#x003b2; have been associated with cognitive dysfunction. Increased A&#x003b2; plaque deposition, identified by positron emission tomography (PET), was associated with decreased episodic memory performance and global cognitive function in healthy older adults, mild cognitive impairment (MCI), and AD participants [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Though executive dysfunction is a characteristic of early AD [<xref ref-type="bibr" rid="CR15">15</xref>], few studies have assessed the potential impact of A&#x003b2; on executive functions. One published study found no association between high A&#x003b2; deposition and executive functions in MCI; however, the assessment of executive functions was limited to a composite of inhibition and verbal fluency [<xref ref-type="bibr" rid="CR16">16</xref>]. Another study found that baseline global A&#x003b2; deposition in frontal, parietal, and medial temporal cortices was associated with greater decreases in executive functions, language, attention, information processing speed, and visuospatial function at 2-year follow-up in people with MCI [<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, several recent studies have reported an association between amyloid and decreased mobility. Specifically, increased amyloid was associated with decreased gait speed in cognitively normal and mildly impaired older adults [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. One study assessing specific gait parameters reported slower gait speed, lower cadence, longer double support time, and greater stance time variability in older adults with high amyloid [<xref ref-type="bibr" rid="CR20">20</xref>]. Of particular relevance to our study, a 12-month prospective study found that higher A&#x003b2; deposition was associated with a faster time to first fall in community-dwelling healthy older adults [<xref ref-type="bibr" rid="CR21">21</xref>]. These results indicate that A&#x003b2; may have an effect on both cognitive and mobility outcomes.</p><p id="Par24">Although previous studies have begun to evaluate the impact of A&#x003b2; on cognitive and physical function in healthy older adults, MCI, and AD participants [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], such studies in people with SIVCI are more limited [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Furthermore, previous studies lack a comprehensive assessment of executive functions, information processing speed, and to our knowledge, no studies have assessed falls risk [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Also, much of current knowledge is based on cross-sectional studies and few studies have assessed the association of cerebral A&#x003b2; on changes in cognitive and mobility outcomes. To address these knowledge gaps, we conducted a secondary analysis to assess the association of A&#x003b2; with changes in cognitive function (i.e., global cognition, executive functions, and information processing speed) and falls risk over a 12-month period. We hypothesized that elevated A&#x003b2; plaque deposition would be associated with larger decrements in these measures over a 12-month period.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par25">Ethical approval was obtained from the Vancouver Coastal Health Research Institute (V07&#x02013;01160) and the University of British Columbia&#x02019;s Clinical Research Ethics Board (H07&#x02013;01160). All subjects gave written informed consent in accordance with the Declaration of Helsinki.</p><sec id="Sec3"><title>Participants and study design</title><p id="Par26">This was a planned secondary analysis of data acquired from a proof-of-concept randomized controlled trial (RCT) of aerobic exercise in people with SIVCI (NCT01027858) [<xref ref-type="bibr" rid="CR24">24</xref>]. Briefly, participants were randomized to either a 6-month thrice-weekly aerobic exercise training group or a usual care control group. Participants were followed for an additional 6-months after completing the 6-month intervention period. Assessments for cognitive functions and falls risk were performed at baseline, 6-month, and 12-month time points. To maximize our ability to detect changes in cognitive function and falls risk, we used baseline and 12-month data for our analyses.</p><p id="Par27">Participants were recruited from the University of British Columbia Hospital Clinic for AD and Related Disorders, the Vancouver General Hospital Stroke Prevention Clinic, and specialized geriatric clinics in Metro Vancouver, British Columbia. The diagnosis of SIVCI was confirmed in each participant by a neurologist based on the presence of cerebral small vessel disease and cognitive impairment [<xref ref-type="bibr" rid="CR25">25</xref>]. A clinical MRI or computed tomography (CT) scan was used to determine the presence of cerebral small vessel disease which was based on the presence of periventricular and deep white matter lesions and at least one lacunar infarct and the absence of non-lacunar territorial (cortical and/or cortico-subcortical) strokes or other specific causes of white matter lesions (i.e. MS, leukodystrophies, sarcoidosis, brain irradiation). Mild cognitive impairment was defined as a Montreal Cognitive Assessment (MOCA) score&#x000a0;&#x0003c;&#x000a0;26/30 at baseline [<xref ref-type="bibr" rid="CR26">26</xref>]. SIVCI diagnosis also required evidence of progressive cognitive decline (compared with previous level of cognitive function) as confirmed through medical records or caregiver/family member interviews. Overall, participants were generally functioning independently and living in the community with minimal assistance by family or caregiver.</p><p id="Par28">Study Inclusion Criteria: Both inclusion and exclusion criteria have been published previously [<xref ref-type="bibr" rid="CR24">24</xref>]. Briefly, individuals were eligible for study entry if they met the following criteria: 1) aged 55&#x000a0;years or older; 2) MOCA score&#x000a0;&#x0003c;&#x000a0;26/30 at screening [<xref ref-type="bibr" rid="CR26">26</xref>]; 3) Mini-Mental State Examination score (MMSE)&#x000a0;&#x02265;&#x000a0;20 at screening [<xref ref-type="bibr" rid="CR27">27</xref>]; 4) if participants are on cognitive medications (e.g. donepezil, galantamine, rivastigmine, memantine, etc.) they must be on a stable and fixed dose that is not expected to change during the 12-month study period, or, if they are not on any of these medications, they are not expected to start them during the 12-month study period; and 5) provide written informed consent. Exclusion criteria included: 1) diagnosed with dementia of any type (e.g. Alzheimer&#x02019;s disease, dementia with lewy bodies, frontal-temporal dementia) or other neurological conditions (e.g. multiple sclerosis, Parkinson&#x02019;s disease); 2) taking medications that may negatively affect cognitive function; and 3) participation in a clinical drug trial concurrent to this study.</p><p id="Par29">This analysis included a sub-set of 22 participants (exercise group <italic>n</italic>&#x000a0;=&#x000a0;11; control group <italic>n</italic>&#x000a0;=&#x000a0;11) who met the overall study eligibility criteria and volunteered to complete a PET scan.</p></sec><sec id="Sec4"><title>Descriptive variables</title><p id="Par30">At baseline, we collected information regarding age, sex, body mass index, waist-hip ratio, and comorbid conditions were measured using the Functional Comorbidity Index. In addition, we report WMH volume for a subsample of participants.</p></sec><sec id="Sec5"><title>Dependent variables</title><sec id="Sec6"><title>Global cognitive function</title><p id="Par31">ADAS-Cog: This test primarily measures memory, language, and praxis. There are 11 items and scores range from 0 to 70 with higher scores indicating greater cognitive dysfunction [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec7"><title>Executive functions</title><p id="Par32">Trail Making Test (Part B minus A): This test primarily measures set shifting [<xref ref-type="bibr" rid="CR29">29</xref>]. Participants were asked to draw lines connecting encircled numbers sequentially (Part A) and to alternate between numbers and letters (Part B). The difference in time to complete Part B and Part A was calculated; smaller difference indicated better performance.</p><p id="Par33">Verbal Digit Span Test (Forward minus Backward): This test primarily measures working memory [<xref ref-type="bibr" rid="CR30">30</xref>]. Participants repeated progressively longer random number sequences in the same order as presented (forward) and in the reversed order (backward). The difference in score between the two tests was calculated; smaller difference indicated better performance.</p><p id="Par34">Stroop Test: This test primarily measures selective attention and conflict resolution [<xref ref-type="bibr" rid="CR31">31</xref>]. Participants completed three conditions (80 trials each): 1) reading out color words printed in black ink; 2) reading out the display color of colored-X&#x02019;s; and 3) participants were shown a page with color-words printed in incongruent colored inks and were asked to name the ink color in which the words were printed. The time difference between the third condition and second condition was calculated; smaller difference indicated better performance.</p></sec><sec id="Sec8"><title>Information processing speed</title><p id="Par35">Digit Symbol Substitution Test (DSST): This test primarily measures information processing speed and psychomotor speed [<xref ref-type="bibr" rid="CR29">29</xref>]. Participants were first presented with a legend of numbers (1 to 9) and their corresponding symbols. They were then presented with a series of numbers, organized in a pre-defined random order, and were asked to fill in the corresponding symbol. Participants were given 90&#x000a0;s to complete the task. A higher number of correct answers in this time period indicated better performance.</p></sec><sec id="Sec9"><title>Falls risk</title><p id="Par36">Physiological Profile Assessment (PPA): This test assesses falls risk [<xref ref-type="bibr" rid="CR32">32</xref>]. The PPA involves the following subscales: 1) proprioception; 2) edge contrast sensitivity; 3) quadriceps strength; 4) hand reaction time; and 5) postural sway. Each item has a relative weighting and a summary z-score is calculated that indicates: mild risk (0&#x02013;1); moderate risk (1&#x02013;2); high risk (2&#x02013;3); and marked risk for future fall (3 and above) [<xref ref-type="bibr" rid="CR32">32</xref>]. The PPA is a reliable [<xref ref-type="bibr" rid="CR33">33</xref>] and valid [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] measure of falls risk in older adults.</p></sec></sec><sec id="Sec10"><title>Independent variable</title><sec id="Sec11"><title>Amyloid-&#x003b2; imaging</title><p id="Par37">Details of the A&#x003b2; imaging protocol have been published previously [<xref ref-type="bibr" rid="CR12">12</xref>]. PET scans were performed using <sup>11</sup>C&#x02013;Pittsburgh Compound-B (PIB) produced at UBC TRIUMF. Scans were performed in 3-D mode using the GE Advance tomograph (General Electric, Canada/USA). A 90-min dynamic acquisition started at tracer injection and data were framed into a 18&#x000a0;&#x000d7;&#x000a0;300 sec imaging sequence.</p><p id="Par38">Parametric images of the non-displaceable binding potential (BP<sub>ND</sub>) [<xref ref-type="bibr" rid="CR36">36</xref>] were generated using tissue input Logan graphical analysis [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] with the cerebellum as the reference region [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. A mean PIB-PET image was created by averaging radiotracer concentration over the entire scan duration &#x02013; this image was used for co-registration and ROI definition purposes. Using SPM 8 (Wellcome Department of Cognitive Neurology, Institute of Neurology, University College London) each subject&#x02019;s T1-weighted MRI image was co-registered to the corresponding mean PIB-PET image. Each subject&#x02019;s MRI image was then normalized to the SPM MNI305 template and the corresponding transformation parameters were applied to the subject&#x02019;s PET images (mean and parametric images). For those without MRI scans (5 subjects did not scan due to MR contraindications), the subject&#x02019;s mean PIB-PET image was normalized to an average PIB-PET image template of 6 healthy control participants.</p><p id="Par39">Regions of interest (ROIs) analysis: A custom set of ROIs was defined on the coronal view of the MNI305 template [<xref ref-type="bibr" rid="CR41">41</xref>]. These ROIs were transposed to each subject&#x02019;s warped MRI and mean-PET images (in MNI space) and adjusted as necessary. The modified set of ROIs was then applied to the parametric PIB-PET image and the average PIB BP<sub>ND</sub> within each ROI was extracted. Global PIB binding was determined by averaging values in bilateral frontal (combined orbitofrontal and medial prefrontal cortex), parietal (combined angular gyrus, superior parietal, precuneus, and supramarginal gyrus), temporal (combined lateral temporal and middle temporal gyrus), and occipital cortices, striatum (putamen and caudate nucleus), and anterior and posterior cingulate gyrus [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par40">All statistical analyses were performed using Statistical Package for the Social Sciences 22.0. We conducted a hierarchical multiple linear regression to determine the unique contribution of A&#x003b2;&#x000a0;plaque deposition on 12-month change in cognitive function and falls risk. We controlled for experimental group (i.e. aerobic exercise training or usual care control) and baseline score. Age was initially included as a covariate but it did not significantly alter the results and was removed for a parsimonious model. The dependent variable for all models was change in the outcome of interest. Change in ADAS-Cog, Trail Making Test, Verbal Digit Span Test, Stroop Test, and PPA was calculated as baseline minus 12-month scores. Change in DSST was calculated as12-month minus baseline scores. In all instances, higher change scores represent improved performance. We report adjusted <italic>R</italic>
<sup>2</sup> values, which penalizes the explained variance for each additional covariate, resulting in a more realistic estimate of explained variance. For each hierarchical regression model, we computed collinearity statistics (tolerance and variance inflation factor), histograms of the residuals, and scatterplots of the predicted versus residual values to ensure that the assumptions of linear regression were met. In all models, mutlicollinearity was not an issue among predictor variables, and the residuals were normally distributed and homoscedastic. To correct for multiple comparisons across all regression models, we applied the Benjamini-Hochberg [<xref ref-type="bibr" rid="CR42">42</xref>] procedure to obtain a false discovery rate (FDR) corrected threshold using alpha&#x000a0;=&#x000a0;0.05.</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>Descriptive variables</title><p id="Par41">The mean age was 72&#x000a0;&#x000b1;&#x000a0;7.91&#x000a0;years (minimum age&#x000a0;=&#x000a0;56&#x000a0;years; maximum age&#x000a0;=&#x000a0;84&#x000a0;years), the average MOCA score was 23.32&#x000a0;&#x000b1;&#x000a0;2.08, and global PIB BP<sub>ND</sub> was 0.10&#x000a0;&#x000b1;&#x000a0;0.23. Six out of 22 participants did not complete an MRI scan &#x02013; 5 people had MR contraindications and 1 MRI scan was discarded due to severe motion artifacts. Among the 16 participants with MRI data, WMH volume ranged from 76.38&#x02013;10,058.89&#x000a0;mm<sup>3</sup> with an average of 2004.40&#x000a0;&#x000b1;&#x000a0;2761.15&#x000a0;mm<sup>3</sup>. Compared with the participants in the RCT that did not complete PIB scans, this subset was similar in age (mean difference&#x000a0;=&#x000a0;3.80, <italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05), but had a higher mean MOCA score (mean difference&#x000a0;=&#x000a0;3.14, <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.05). Detailed demographic characteristics and neuropsychological test results are presented in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Descriptive Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th colspan="2">Exercise group<break/>
<italic>n</italic>&#x000a0;=&#x000a0;11</th><th colspan="2">Control group<break/>
<italic>n</italic>&#x000a0;=&#x000a0;11</th><th colspan="2">Total<break/>
<italic>N</italic>&#x000a0;=&#x000a0;22</th></tr><tr><th/><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>Age</td><td>70.00</td><td>7.29</td><td>73.45</td><td>8.47</td><td>71.73</td><td>7.91</td></tr><tr><td>Female sex, No. (%)</td><td>3</td><td>27.3</td><td>4</td><td>36.4</td><td>7</td><td>31.81</td></tr><tr><td>MOCA</td><td>22.73</td><td>2.20</td><td>23.91</td><td>1.87</td><td>23.32</td><td>2.08</td></tr><tr><td>Waist-to-hip ratio</td><td>0.90</td><td>0.08</td><td>0.93</td><td>0.08</td><td>0.91</td><td>0.08</td></tr><tr><td>Body mass index</td><td>27.14</td><td>6.24</td><td>26.75</td><td>2.98</td><td>26.95</td><td>4.78</td></tr><tr><td>FCI</td><td>3.09</td><td>1.81</td><td>3.55</td><td>1.69</td><td>3.32</td><td>1.73</td></tr><tr><td>Total medications</td><td>3.27</td><td>3.10</td><td>5.00</td><td>3.90</td><td>4.14</td><td>3.55</td></tr><tr><td>Beta-blockers, No. (%)</td><td>3</td><td>27</td><td>2</td><td>18</td><td>5</td><td>23</td></tr><tr><td>Global PIB BP<sub>ND</sub>
</td><td>0.14 </td><td>0.24</td><td>0.07</td><td>0.23</td><td>0.10</td><td>0.23</td></tr><tr><td>WMH volume (mm<sup>3</sup>)</td><td>1277.82<sup>a</sup>
</td><td>1446.90</td><td>2569.52<sup>b</sup>
</td><td>3450.16</td><td>2004.40<sup>c</sup>
</td><td>2761.15</td></tr><tr><td colspan="7">Baseline Assessments</td></tr><tr><td>&#x02003;ADAS-Cog</td><td>10.65</td><td>4.76</td><td>8.61</td><td>2.60</td><td>9.63</td><td>3.88</td></tr><tr><td>&#x02003;TMT B-A, sec.</td><td>45.07</td><td>20.93</td><td>55.95</td><td>28.14</td><td>50.51</td><td>24.84</td></tr><tr><td>&#x02003;VDST F-B, sec.</td><td>2.45</td><td>2.88</td><td>4.00</td><td>2.61</td><td>3.23</td><td>2.79</td></tr><tr><td>&#x02003;Stroop CW-C, sec.</td><td>68.33</td><td>30.26</td><td>54.54</td><td>20.02</td><td>61.44</td><td>26.01</td></tr><tr><td>&#x02003;DSST</td><td>26.27</td><td>8.01</td><td>25.27</td><td>5.97</td><td>25.77</td><td>6.91</td></tr><tr><td>&#x02003;PPA</td><td>0.54</td><td>1.50</td><td>0.47</td><td>0.91</td><td>0.50</td><td>1.21</td></tr><tr><td colspan="7">Final Assessments</td></tr><tr><td>&#x02003;ADAS-Cog</td><td>9.57</td><td>4.70</td><td>6.86</td><td>2.77</td><td>8.22</td><td>4.01</td></tr><tr><td>&#x02003;TMT B-A, sec.</td><td>76.43</td><td>69.32</td><td>66.45</td><td>51.88</td><td>71.44</td><td>59.97</td></tr><tr><td>&#x02003;VDST F-B, sec.</td><td>2.18</td><td>1.83</td><td>3.27</td><td>1.85</td><td>2.73</td><td>1.88</td></tr><tr><td>&#x02003;Stroop CW-C, sec.</td><td>66.41</td><td>25.91</td><td>55.60</td><td>32.37</td><td>61.00</td><td>29.14</td></tr><tr><td>&#x02003;DSST</td><td>26.09</td><td>8.93</td><td>23.55</td><td>8.47</td><td>24.82</td><td>8.59</td></tr><tr><td>&#x02003;PPA</td><td>0.12</td><td>1.23</td><td>0.54</td><td>0.59</td><td>0.33</td><td>0.96</td></tr></tbody></table><table-wrap-foot><p>
<italic>SD</italic> Standard Deviation, <italic>MOCA</italic> Montreal Cognitive Assessment (max. Score 30), <italic>FCI</italic> Functional comorbidity index (total number of comorbidities), <italic>ADAS-Cog</italic> Alzheimer&#x02019;s Disease Assessment Scale - Cognitive subscale (max. Score of 70), <italic>TMT B-A</italic> Trail Making Test, Part B minus Part A, <italic>VDST F-B</italic> Verbal Digit Span Test, Forward minus Backward, <italic>Stroop CW-W</italic> Stroop Color Words minus Stroop colored x&#x02019;s, <italic>DSST</italic> Digit Symbol Substitution Test, <italic>PPA</italic> Physiological Profile Assessment; <sup>a</sup>Exercise group - WMH volume, <italic>n</italic>&#x000a0;=&#x000a0;7; <sup>b</sup>Control group - WMH volume, <italic>n</italic>&#x000a0;=&#x000a0;9; <sup>c</sup>Total - WMH volume, <italic>n</italic>&#x000a0;=&#x000a0;16</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec15"><title>Global cognitive function</title><p id="Par42">ADAS-Cog: PIB BP<sub>ND</sub> was not significantly associated with change in ADAS-Cog (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05).</p></sec><sec id="Sec16"><title>Executive functions</title><p id="Par43">Trail Making Test (Part B minus A): Higher PIB BP<sub>ND</sub> was significantly associated with decreased set shifting (&#x003b2;&#x000a0;=&#x000a0;&#x02212;0.68, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), the total adjusted variance accounted by the final model was 38.5% &#x02013; Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Multiple regression model assessing the contribution of amyloid on change in Trail Making Test</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Independent variables</th><th>R<sup>2</sup>
</th><th>Adjusted R<sup>2</sup>
</th><th>R<sup>2</sup> change</th><th>Unstandardized B (Standard error)</th><th>Standardized &#x003b2;</th><th>
<italic>P</italic>- value</th></tr></thead><tbody><tr><td>Step 1</td><td char="." align="char">0.04</td><td char="." align="char">&#x02212;0.07</td><td char="." align="char">0.04</td><td/><td/><td>0.70</td></tr><tr><td>Group</td><td/><td/><td/><td>20.16 (25.44)</td><td>0.18</td><td>0.44</td></tr><tr><td>TMT baseline</td><td/><td/><td/><td>0.07 (0.52)</td><td>0.03</td><td>0.90</td></tr><tr><td>Step 2</td><td char="." align="char">0.47</td><td char="." align="char">0.39</td><td char="." align="char">0.44<sup>a</sup>
</td><td/><td/><td>&#x0003c;0.01</td></tr><tr><td>Group</td><td/><td/><td/><td>5.42 (19.70)</td><td>0.05</td><td>0.79</td></tr><tr><td>TMT baseline</td><td/><td/><td/><td>0.40 (0.41)</td><td>0.18</td><td>0.34</td></tr><tr><td>PIB BP<sub>ND</sub>
</td><td/><td/><td/><td>&#x02212;166.43 (43.09)</td><td>&#x02212;0.68</td><td>&#x0003c;0.01</td></tr></tbody></table><table-wrap-foot><p>
<italic>TMT</italic> Trail Making Test, Part B minus Part A baseline score</p><p>
<sup>a</sup>Significant after FDR adjustment</p></table-wrap-foot></table-wrap>
</p><p id="Par44">Verbal Digit Span Test (Forward minus Backward<italic>)</italic>: PIB BP<sub>ND</sub> was not significantly associated with change in working memory (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05).</p><p id="Par45">Stroop Test: Higher PIB BP<sub>ND</sub> was significantly associated with decreased selective attention and conflict resolution (&#x003b2;&#x000a0;=&#x000a0;&#x02212;0.54, <italic>p</italic>&#x000a0;=&#x000a0;0.01), the total adjusted variance accounted by the final model was 31.4% &#x02013; Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Multiple regression model assessing the contribution of amyloid on change in Stroop Test</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Independent variables</th><th>R<sup>2</sup>
</th><th>Adjusted R<sup>2</sup>
</th><th>R<sup>2</sup> change</th><th>Unstandardized B (Standard error)</th><th>Standardized &#x003b2;</th><th>
<italic>P</italic>- value</th></tr></thead><tbody><tr><td>Step 1</td><td char="." align="char">0.13</td><td char="." align="char">0.04</td><td char="." align="char">0.13</td><td/><td/><td>0.26</td></tr><tr><td>Group</td><td/><td/><td/><td>2.12 (11.12)</td><td>0.04</td><td>0.85</td></tr><tr><td>Stroop baseline</td><td/><td/><td/><td>0.37 (0.22)</td><td>0.38</td><td>0.11</td></tr><tr><td>Step 2</td><td char="." align="char">0.41</td><td char="." align="char">0.31</td><td char="." align="char">0.28<sup>a</sup>
</td><td/><td/><td>0.01</td></tr><tr><td>Group</td><td/><td/><td/><td>&#x02212;0.74 (9.46)</td><td>&#x02212;0.02</td><td>0.94</td></tr><tr><td>Stroop baseline</td><td/><td/><td/><td>0.45 (0.19)</td><td>0.46</td><td>0.03</td></tr><tr><td>PIB BP<sub>ND</sub>
</td><td/><td/><td/><td>&#x02212;59.67 (20.46)</td><td>&#x02212;0.54</td><td>0.01</td></tr></tbody></table><table-wrap-foot><p>
<italic>Stroop CW-W</italic> Stroop Color Words minus Stroop colored x&#x02019;s baseline score</p><p>
<sup>a</sup>Significant after FDR adjustment</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec17"><title>Information processing speed</title><p id="Par46">DSST: Higher PIB BP<sub>ND</sub> was significantly associated with decreased information processing speed (&#x003b2;&#x000a0;=&#x000a0;&#x02212;0.56, <italic>p</italic>&#x000a0;=&#x000a0;0.01), the total adjusted variance accounted by the final model was 20.6% &#x02013; Table <xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Multiple regression model assessing the contribution of amyloid on change in Digit Symbol Substitution Test</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Independent variables</th><th>R<sup>2</sup>
</th><th>Adjusted R<sup>2</sup>
</th><th>R<sup>2</sup> change</th><th>Unstandardized B (Standard error)</th><th>Standardized &#x003b2;</th><th>
<italic>P</italic>- value</th></tr></thead><tbody><tr><td>Step 1</td><td char="." align="char">0.02</td><td char="." align="char">&#x02212;0.08</td><td char="." align="char">0.02</td><td/><td/><td>0.79</td></tr><tr><td>Group</td><td/><td/><td/><td>&#x02212;1.55 (2.26)</td><td>&#x02212;0.16</td><td>0.50</td></tr><tr><td>DSST baseline</td><td/><td/><td/><td>&#x02212;0.01 (0.17)</td><td>&#x02212;0.01</td><td>0.96</td></tr><tr><td>Step 2</td><td char="." align="char">0.32</td><td char="." align="char">0.21</td><td char="." align="char">0.30<sup>a</sup>
</td><td/><td/><td>0.01</td></tr><tr><td>Group</td><td/><td/><td/><td>&#x02212;2.45 (1.97)</td><td>&#x02212;0.25</td><td>0.23</td></tr><tr><td>DSST baseline</td><td/><td/><td/><td>&#x02212;0.09 (0.15)</td><td>&#x02212;0.12</td><td>0.56</td></tr><tr><td>PIB BP<sub>ND</sub>
</td><td/><td/><td/><td>&#x02212;12.31 (4.41)</td><td>&#x02212;0.56</td><td>0.01</td></tr></tbody></table><table-wrap-foot><p>
<italic>DSST</italic> Digit Symbol Substitution Test baseline score</p><p>
<sup>a</sup>Significant after FDR adjustment</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec18"><title>Falls risk</title><p id="Par47">PPA: Increased PIB BP<sub>ND</sub> was significantly associated with increased falls risk (&#x003b2;&#x000a0;=&#x000a0;&#x02212;0.39, <italic>p</italic>&#x000a0;=&#x000a0;0.03), the total adjusted variance accounted by the final model was 51.3% &#x02013; Table <xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Multiple regression model assessing the contribution of amyloid on change in Physiological Profile Assessment</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Independent variables</th><th>R<sup>2</sup>
</th><th>Adjusted R<sup>2</sup>
</th><th>R<sup>2</sup> change</th><th>Unstandardized B (Standard error)</th><th>Standardized &#x003b2;</th><th>
<italic>P</italic>- value</th></tr></thead><tbody><tr><td>Step 1</td><td char="." align="char">0.45</td><td char="." align="char">0.39</td><td char="." align="char">0.45</td><td/><td/><td>&#x0003c;0.01 </td></tr><tr><td>Group</td><td/><td/><td/><td>&#x02212;0.45 (0.32)</td><td>&#x02212;0.24</td><td>0.17</td></tr><tr><td>PPA baseline</td><td/><td/><td/><td>0.49 (0.13)</td><td>0.62</td><td>&#x0003c;0.01</td></tr><tr><td>Step 2</td><td char="." align="char">0.58</td><td char="." align="char">0.51</td><td char="." align="char">0.13<sup>a</sup>
</td><td/><td/><td>0.03</td></tr><tr><td>Group</td><td/><td/><td/><td>&#x02212;0.56 (0.29)</td><td>&#x02212;0.30</td><td>0.07</td></tr><tr><td>PPA baseline</td><td/><td/><td/><td>0.39 (0.13)</td><td>0.50</td><td>0.01</td></tr><tr><td>PIB BP<sub>ND</sub>
</td><td/><td/><td/><td>&#x02212;1.60 (0.67)</td><td>&#x02212;0.39</td><td>0.03</td></tr></tbody></table><table-wrap-foot><p>
<italic>PPA</italic> Physiological Profile Assessment baseline score</p><p>
<sup>a</sup>Significant after FDR adjustment</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par48">Currently, much of our knowledge on the effects of co-existing A&#x003b2; pathology in SIVCI is based on cross-sectional studies [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] and little is known about their impact on changes in cognitive function and mobility over time. We found that higher A&#x003b2; deposition was associated with greater decrements in set shifting, attention and conflict resolution , and information processing speed over a 12-month period. In addition, we found that people with greater A&#x003b2; deposition displayed increased falls risk at follow-up. These results indicate that co-existing A&#x003b2; plaque deposition may play a role in subsequent cognitive and mobility declines in older adults with SIVCI.</p><p id="Par49">Previous studies assessing the role of A&#x003b2; on cognitive function in SIVCI have produced equivocal results. One study found that A&#x003b2; was correlated with decreased performance on tests of immediate and delayed recall of verbal learning but not executive functions [<xref ref-type="bibr" rid="CR22">22</xref>]. Another study found that A&#x003b2; was independently associated with cognitive impairment in multiple domains, including language, visuospatial, memory, and executive functions [<xref ref-type="bibr" rid="CR11">11</xref>]. A published cross-sectional analysis of this data set found that increased A&#x003b2; plaque deposition was associated with poorer performance in global cognitive function as measured by ADAS-Cog [<xref ref-type="bibr" rid="CR12">12</xref>]. In the current analysis, we did not find an association between A&#x003b2; plaque deposition and change in global cognitive function; however, we found that greater A&#x003b2; deposition was associated with declines in specific executive processes and information processing speed over 12-months.</p><p id="Par50">Our findings suggest that symptoms associated with SIVCI (i.e. executive dysfunction and decreased information processing speed) are amplified by secondary A&#x003b2; pathology. Few studies have been conducted to assess the impact of A&#x003b2; on change in cognitive function in people with a clinical diagnosis of SIVCI. The Amyloid PET Imaging for Subcortical Vascular Dementia (AMPETIS) study found that PIB positivity was associated with faster declines in attention, visuospatial skills, visual memory, episodic memory, and verbal learning, but no significant declines in executive functions were detected [<xref ref-type="bibr" rid="CR23">23</xref>]. However, we note that only a single executive measure was included &#x02013; phonemic and semantic verbal fluency. Although verbal fluency tests do involve aspects of executive control, they do not isolate the three main components of executive functions: set shifting, working memory/updating, and inhibition of dominant responses [<xref ref-type="bibr" rid="CR43">43</xref>] &#x02013; which we targeted in the present study. Furthermore, we report that greater A&#x003b2; plaque deposition is associated with reduced information processing speed over time. In summary, these preliminary analyses indicated that co-existing A&#x003b2; plaques may be detrimental to multiple domains of cognitive function in people with SIVCI.</p><p id="Par51">We also found that increased A&#x003b2; plaque deposition was associated with increased falls risk. This concurs with previous literature &#x02013; a study in healthy community-dwelling older adults found that higher A&#x003b2; was associated with faster time to first fall over 12-months [<xref ref-type="bibr" rid="CR21">21</xref>]. In addition, epidemiological studies found that 42% of a community sample with mild to moderately severe AD fell within a 12-month period [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. This is supported by studies that have identified impaired static and dynamic balance, mobility, and gait dysfunction in early AD [<xref ref-type="bibr" rid="CR45">45</xref>], which may contribute to an increased risk of falling. Furthermore, there is a strong association between cognition, particularly executive functions, with gait and balance. Older people with poor executive control walk slower, have increased stride variability, have poorer performance on complex mobility tasks, and fall more often [<xref ref-type="bibr" rid="CR46">46</xref>]. Executive dysfunction may impair planning, control, and execution of movements, and thus, can increase falls risk [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par52">Our findings are not without limitations. First, this study was a secondary analysis of an exercise intervention trial and it is unclear how exercise may have influenced cognitive function and falls risk. To minimize exercise effects, we statistically controlled for group membership. Second, our small sample size requires that these findings be confirmed in larger follow-up studies. Third, we did not control for the presence of other AD and SIVCI pathologies such as NFT, lacunes, or WMH. This is important to note, as NFT have been associated with cognitive outcomes in AD. Lacunes and WMH have been associated with both executive dysfunctions and falls risk. However, the presence of A&#x003b2; has also been associated with executive functions and falls risk in people with MCI and AD, indicating a unique contribution of A&#x003b2; on cognitive and mobility declines. Within a subset of this data with WMH volume quantification, including WMH volume and age as covariates did not significantly alter the results. As such, it is plausible that A&#x003b2; plaque deposition may independently contribute to changes in cognitive function and falls risk in SIVCI.</p></sec><sec id="Sec20"><title>Conclusions</title><p id="Par53">The results of this study suggest that cerebral A&#x003b2; plaque deposition is associated with greater declines in both executive functions and information processing speed, as well as greater increases in falls risk among older adults with a primary SIVCI diagnosis. However, more studies with larger samples and longer follow-up are needed to fully elucidate the impact of co-existing A&#x003b2; on disease progression in SIVCI. Future therapies for SIVCI may need to account for the potential presence and effect of amyloid for the optimal care of those with SIVCI.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AD</term><def><p id="Par6">Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>A&#x003b2;</term><def><p id="Par7">Amyloid-beta</p></def></def-item><def-item><term>BP<sub>ND</sub></term><def><p id="Par8">Non-displaceable binding potential</p></def></def-item><def-item><term>CT</term><def><p id="Par9">Computed tomography</p></def></def-item><def-item><term>DSST</term><def><p id="Par10">Digit Symbol Substitution Test</p></def></def-item><def-item><term>FDR</term><def><p id="Par11">False discovery rate</p></def></def-item><def-item><term>MCI</term><def><p id="Par12">Mild cognitive impairment</p></def></def-item><def-item><term>NFT</term><def><p id="Par13">Neurofibrillary tangles</p></def></def-item><def-item><term>PET</term><def><p id="Par14">Positron emission tomography</p></def></def-item><def-item><term>PIB</term><def><p id="Par15">
<sup>11</sup>C Pittsburgh compound B</p></def></def-item><def-item><term>PPA</term><def><p id="Par16">Physiological Profile Assessment</p></def></def-item><def-item><term>RCT</term><def><p id="Par17">Randomized controlled trial</p></def></def-item><def-item><term>ROI</term><def><p id="Par18">Regions of interest</p></def></def-item><def-item><term>SIVCI</term><def><p id="Par19">Subcortical ischemic vascular cognitive impairment</p></def></def-item><def-item><term>WMH</term><def><p id="Par20">White matter hyperintensities</p></def></def-item></def-list></glossary><ack><p>UBC TRIUMF is gratefully acknowledged for PET tracer production.</p><sec id="FPar1"><title>Funding</title><p id="Par54">This study was jointly funded by the Canadian Stroke Network, Heart and Stroke Foundation of Canada, and Jack Brown &#x00026; Family Alzheimer&#x02019;s Research Foundation.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par55">The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p id="Par56">All authors (ED, JRB, GYRH, VS, CJ, RT and TLA) contributed to study design, statistical analysis, data interpretation, and manuscript preparation. The final version of this manuscript was approved by all authors.</p></sec><sec id="FPar4"><title>Competing interests</title><p id="Par57">The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par58">Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p id="Par59">Ethical approval was obtained from the Vancouver Coastal Health Research Institute (V07&#x02013;01160) and the University of British Columbia&#x02019;s Clinical Research Ethics Board (H07&#x02013;01160). All subjects gave written informed consent in accordance with the Declaration of Helsinki.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par60">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>KA</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name></person-group><article-title>Prevalence of dementia disorders in the oldest-old: an autopsy study</article-title><source>Acta Neuropathol</source><year>2010</year><volume>119</volume><issue>4</issue><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0654-5</pub-id><pub-id pub-id-type="pmid">20204386</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Bang</surname><given-names>W</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title><source>Neurology</source><year>2007</year><volume>69</volume><issue>24</issue><fpage>2197</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000271090.28148.24</pub-id><pub-id pub-id-type="pmid">17568013</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattson</surname><given-names>MP</given-names></name></person-group><article-title>Pathways towards and away from Alzheimer's disease</article-title><source>Nature</source><year>2004</year><volume>430</volume><issue>7000</issue><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1038/nature02621</pub-id><pub-id pub-id-type="pmid">15295589</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Rockwood K, Macknight C, Wentzel C, Black S, Bouchard R, Gauthier S, et al. The diagnosis of "mixed" dementia in the consortium for the investigation of vascular impairment of cognition (CIVIC). Ann N Y Acad Sci. 2000;903:522&#x02013;8.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esiri</surname><given-names>MM</given-names></name><name><surname>Nagy</surname><given-names>Z</given-names></name><name><surname>Smith</surname><given-names>MZ</given-names></name><name><surname>Barnetson</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name></person-group><article-title>Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease</article-title><source>Lancet</source><year>1999</year><volume>354</volume><issue>9182</issue><fpage>919</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)02355-7</pub-id><pub-id pub-id-type="pmid">10489957</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56(2):165&#x02013;70.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalaria</surname><given-names>RN</given-names></name></person-group><article-title>The role of cerebral ischemia in Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><issue>2</issue><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00125-1</pub-id><pub-id pub-id-type="pmid">10867217</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadecola</surname><given-names>C</given-names></name></person-group><article-title>The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia</article-title><source>Acta Neuropathol</source><year>2010</year><volume>120</volume><issue>3</issue><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0718-6</pub-id><pub-id pub-id-type="pmid">20623294</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marnane</surname><given-names>M</given-names></name><name><surname>Hsiung</surname><given-names>GY</given-names></name></person-group><article-title>Could better phenotyping small vessel disease provide new insights into Alzheimer disease and improve clinical trial outcomes?</article-title><source>Curr Alzheimer Res</source><year>2016</year><volume>13</volume><issue>7</issue><fpage>750</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.2174/1567205013666160222112634</pub-id><pub-id pub-id-type="pmid">26899579</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Seo</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment</article-title><source>Neurobiol Aging</source><year>2014</year><volume>35</volume><issue>1</issue><fpage>254</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.06.026</pub-id><pub-id pub-id-type="pmid">23932881</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Lee MJ, Seo SW, Na DL, Kim C, Park JH, Kim GH, et al. Synergistic effects of ischemia and beta-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment. JAMA psychiatry. 2014;71(4):412&#x02013;22.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Dao E, Hsiung GY, Sossi V, Jacova C, Tam R, Dinelle K, et al. Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment. BMC Neurol. 2015;15:197.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain : a journal of neurology. 2007;130(Pt 11):2837&#x02013;44.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Bra&#x00161;i&#x00107; JR, et al. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am J Geriatr Psychiatry. 2013;21(3):272&#x02013;8.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Wicklund</surname><given-names>AH</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name></person-group><article-title>The neuropsychological profile of Alzheimer disease</article-title><source>Cold Spring Harbor perspectives in medicine</source><year>2012</year><volume>2</volume><issue>4</issue><fpage>a006171</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a006171</pub-id><pub-id pub-id-type="pmid">22474609</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>YY</given-names></name><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Pietrzak</surname><given-names>RH</given-names></name><name><surname>Ames</surname><given-names>D</given-names></name><name><surname>Ellis</surname><given-names>KA</given-names></name><name><surname>Harrington</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer&#x02019;s disease</article-title><source>Brain : a journal of neurology</source><year>2014</year><volume>137</volume><issue>1</issue><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1093/brain/awt286</pub-id><pub-id pub-id-type="pmid">24176981</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>GW</given-names></name><name><surname>Siddarth</surname><given-names>P</given-names></name><name><surname>Kepe</surname><given-names>V</given-names></name><etal/></person-group><article-title>Prediction of cognitive decline by positron emission tomography of brain amyloid and tau</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><issue>2</issue><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.559</pub-id><pub-id pub-id-type="pmid">22332188</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Campo</surname><given-names>N</given-names></name><name><surname>Payoux</surname><given-names>P</given-names></name><name><surname>Djilali</surname><given-names>A</given-names></name><name><surname>Delrieu</surname><given-names>J</given-names></name><name><surname>Hoogendijk</surname><given-names>EO</given-names></name><name><surname>Rolland</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Relationship of regional brain beta-amyloid to gait speed</article-title><source>Neurology</source><year>2016</year><volume>86</volume><issue>1</issue><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002235</pub-id><pub-id pub-id-type="pmid">26643548</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Nadkarni NK, Perera S, Snitz BE, Mathis CA, Price J, Williamson JD, et al. Association of brain amyloid-beta with slow gait in elderly individuals without dementia: influence of cognition and apolipoprotein E epsilon4 genotype. JAMA neurology. 2017;74(1):82&#x02013;90.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Wennberg AMV, Savica R, Hagen CE, Roberts RO, Knopman DS, Hollman JH, Vemuri P, Jack CR, Petersen RC, Mielke MM. Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. J Am Geriatr Soc. 2017;65(4):792&#x02013;9.</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Stark SL, Roe CM, Grant EA, Hollingsworth H, Benzinger TL, Fagan AM, et al. Preclinical Alzheimer disease and risk of falls. Neurology. 2013;81(5):437&#x02013;43.</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Lee JH, Kim SH, Kim GH, Seo SW, Park HK, Oh SJ, et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology. 2011;77(1):18&#x02013;25.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>BS</given-names></name><name><surname>Seo</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Noh</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia</article-title><source>Neurology</source><year>2015</year><volume>85</volume><issue>19</issue><fpage>1687</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002097</pub-id><pub-id pub-id-type="pmid">26468407</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Liu-Ambrose T, Eng JJ, Boyd LA, Jacova C, Davis JC, Bryan S, et al. Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. BMC Neurol. 2010;10:14.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>V</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name><name><surname>Nyenhuis</surname><given-names>DL</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><etal/></person-group><article-title>National Institute of Neurological Disorders and Stroke-Canadian Stroke network vascular cognitive impairment harmonization standards</article-title><source>Stroke</source><year>2006</year><volume>37</volume><issue>9</issue><fpage>2220</fpage><lpage>2241</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000237236.88823.47</pub-id><pub-id pub-id-type="pmid">16917086</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695&#x02013;9.</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x02013;98.</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirk</surname><given-names>A</given-names></name></person-group><article-title>Target symptoms and outcome measures: cognition</article-title><source>Canad J Neurol Sci</source><year>2007</year><volume>34</volume><issue>Suppl 1</issue><fpage>S42</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1017/S0317167100005552</pub-id><pub-id pub-id-type="pmid">17469681</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Spreen O, Strauss E. A compendium of neuropsychological tests: Administration, norms and commentary. 2nd ed. New York: Oxford University Press; 1998.</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Wechsler D. Wechsler Adult Intelligence Scale&#x02014;Revised. New York: The Psychological Corporation, Harcourt Brace Jovanovich; 1981.</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Graf P, Uttl B, Tuokko H. Color- and picture-word Stroop tests: Performance changes in old age. J Clin Exp Neuropsychol. 1995;17(3):390&#x02013;415.</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>SR</given-names></name><name><surname>Menz</surname><given-names>HB</given-names></name><name><surname>Tiedemann</surname><given-names>A</given-names></name></person-group><article-title>A physiological profile approach to falls risk assessment and prevention</article-title><source>Phys Ther</source><year>2003</year><volume>83</volume><issue>3</issue><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">12620088</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>SR</given-names></name><name><surname>Castell</surname><given-names>S</given-names></name></person-group><article-title>Physical activity program for older persons: effect on balance, strength, neuromuscular control, and reaction time</article-title><source>Arch Phys Med Rehabil</source><year>1994</year><volume>75</volume><issue>6</issue><fpage>648</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/0003-9993(94)90187-2</pub-id><pub-id pub-id-type="pmid">8002763</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>SR</given-names></name><name><surname>Clark</surname><given-names>RD</given-names></name><name><surname>Webster</surname><given-names>IW</given-names></name></person-group><article-title>Physiological factors associated with falls in an elderly population</article-title><source>J Am Geriatr Soc</source><year>1991</year><volume>39</volume><issue>12</issue><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.1991.tb03574.x</pub-id><pub-id pub-id-type="pmid">1960365</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>SR</given-names></name><name><surname>Ward</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>P</given-names></name><name><surname>Anstey</surname><given-names>KJ</given-names></name></person-group><article-title>Physiological factors associated with falls in older community-dwelling women</article-title><source>J Am Geriatr Soc</source><year>1994</year><volume>42</volume><issue>10</issue><fpage>1110</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.1994.tb06218.x</pub-id><pub-id pub-id-type="pmid">7930338</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Innis</surname><given-names>RB</given-names></name><name><surname>Cunningham</surname><given-names>VJ</given-names></name><name><surname>Delforge</surname><given-names>J</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Gjedde</surname><given-names>A</given-names></name><name><surname>Gunn</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Consensus nomenclature for in vivo imaging of reversibly binding radioligands</article-title><source>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</source><year>2007</year><volume>27</volume><issue>9</issue><fpage>1533</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600493</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Ding</surname><given-names>YS</given-names></name><name><surname>Alexoff</surname><given-names>DL</given-names></name></person-group><article-title>Distribution volume ratios without blood sampling from graphical analysis of PET data</article-title><source>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</source><year>1996</year><volume>16</volume><issue>5</issue><fpage>834</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1097/00004647-199609000-00008</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(&#x02212;)-cocaine PET studies in human subjects. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1990;10(5):740&#x02013;7.</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopresti</surname><given-names>BJ</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Mathis</surname><given-names>CA</given-names></name><name><surname>Hoge</surname><given-names>JA</given-names></name><name><surname>Ziolko</surname><given-names>SK</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis</article-title><source>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</source><year>2005</year><volume>46</volume><issue>12</issue><fpage>1959</fpage><lpage>1972</lpage></element-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2005;25(11):1528&#x02013;47.</mixed-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>DL</given-names></name><name><surname>Neelin</surname><given-names>P</given-names></name><name><surname>Peters</surname><given-names>TM</given-names></name><name><surname>Evans</surname><given-names>AC</given-names></name></person-group><article-title>Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space</article-title><source>J Comput Assist Tomogr</source><year>1994</year><volume>18</volume><issue>2</issue><fpage>192</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1097/00004728-199403000-00005</pub-id><pub-id pub-id-type="pmid">8126267</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>J R Stat Soc Ser B Methodol</source><year>1995</year><volume>57</volume><issue>1</issue><fpage>289</fpage><lpage>300</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>A</given-names></name><name><surname>Friedman</surname><given-names>NP</given-names></name><name><surname>Emerson</surname><given-names>MJ</given-names></name><name><surname>Witzki</surname><given-names>AH</given-names></name><name><surname>Howerter</surname><given-names>A</given-names></name><name><surname>Wager</surname><given-names>TD</given-names></name></person-group><article-title>The unity and diversity of executive functions and their contributions to complex "frontal lobe" tasks: a latent variable analysis</article-title><source>Cogn Psychol</source><year>2000</year><volume>41</volume><issue>1</issue><fpage>49</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1006/cogp.1999.0734</pub-id><pub-id pub-id-type="pmid">10945922</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horikawa</surname><given-names>E</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Iwasaki</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name></person-group><article-title>Risk of falls in Alzheimer's disease: a prospective study</article-title><source>Intern Med</source><year>2005</year><volume>44</volume><issue>7</issue><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.44.717</pub-id><pub-id pub-id-type="pmid">16093593</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suttanon</surname><given-names>P</given-names></name><name><surname>Hill</surname><given-names>KD</given-names></name><name><surname>Said</surname><given-names>CM</given-names></name><name><surname>Logiudice</surname><given-names>D</given-names></name><name><surname>Lautenschlager</surname><given-names>NT</given-names></name><name><surname>Dodd</surname><given-names>KJ</given-names></name></person-group><article-title>Balance and mobility dysfunction and falls risk in older people with mild to moderate Alzheimer disease</article-title><source>American journal of physical medicine &#x00026; rehabilitation / Association of Academic Physiatrists</source><year>2012</year><volume>91</volume><issue>1</issue><fpage>12</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1097/PHM.0b013e31823caeea</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">van Iersel MB, Kessels RP, Bloem BR, Verbeek AL, Olde Rikkert MG. Executive functions are associated with gait and balance in community-living elderly people. J Gerontol Ser A Biol Med Sci. 2008;63(12):1344&#x02013;9.&#x000a0;</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu-Ambrose</surname><given-names>T</given-names></name><name><surname>Nagamatsu</surname><given-names>LS</given-names></name><name><surname>Hsu</surname><given-names>CL</given-names></name><name><surname>Bolandzadeh</surname><given-names>N</given-names></name></person-group><article-title>Emerging concept: 'central benefit model' of exercise in falls prevention</article-title><source>Br J Sports Med</source><year>2013</year><volume>47</volume><issue>2</issue><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1136/bjsports-2011-090725</pub-id><pub-id pub-id-type="pmid">22522589</pub-id></element-citation></ref></ref-list></back></article>